Intrinsic value of Lexicon Pharmaceuticals - LXRX

Previous Close

$16.70

  Intrinsic Value

$32.69

stock screener

  Rating & Target

str. buy

+96%

  Value-price divergence*

+1428%

Previous close

$16.70

 
Intrinsic value

$32.69

 
Up/down potential

+96%

 
Rating

str. buy

 
Value-price divergence*

+1428%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of LXRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -36.15
  50.00
  45.50
  41.45
  37.81
  34.52
  31.57
  28.91
  26.52
  24.37
  22.43
  20.69
  19.12
  17.71
  16.44
  15.29
  14.27
  13.34
  12.50
  11.75
  11.08
  10.47
  9.92
  9.43
  8.99
  8.59
  8.23
  7.91
  7.62
  7.36
  7.12
Revenue, $m
  83
  125
  181
  256
  353
  475
  625
  806
  1,019
  1,268
  1,552
  1,873
  2,232
  2,627
  3,059
  3,526
  4,030
  4,567
  5,138
  5,742
  6,378
  7,046
  7,745
  8,476
  9,238
  10,031
  10,857
  11,715
  12,607
  13,535
  14,498
Variable operating expenses, $m
 
  121
  174
  244
  334
  448
  588
  757
  956
  1,188
  1,454
  1,749
  2,084
  2,453
  2,856
  3,293
  3,763
  4,265
  4,798
  5,362
  5,956
  6,579
  7,232
  7,915
  8,626
  9,367
  10,138
  10,939
  11,773
  12,639
  13,538
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  220
  121
  174
  244
  334
  448
  588
  757
  956
  1,188
  1,454
  1,749
  2,084
  2,453
  2,856
  3,293
  3,763
  4,265
  4,798
  5,362
  5,956
  6,579
  7,232
  7,915
  8,626
  9,367
  10,138
  10,939
  11,773
  12,639
  13,538
Operating income, $m
  -137
  4
  7
  12
  19
  27
  37
  49
  63
  79
  98
  124
  148
  174
  203
  234
  267
  302
  340
  380
  422
  467
  513
  561
  612
  664
  719
  776
  835
  896
  960
EBITDA, $m
  -135
  12
  17
  25
  34
  45
  60
  77
  98
  121
  149
  179
  214
  252
  293
  338
  386
  437
  492
  550
  611
  675
  742
  812
  885
  960
  1,040
  1,122
  1,207
  1,296
  1,388
Interest expense (income), $m
  6
  5
  14
  26
  42
  63
  89
  122
  161
  207
  260
  322
  391
  468
  553
  646
  747
  855
  971
  1,094
  1,224
  1,361
  1,505
  1,656
  1,813
  1,977
  2,148
  2,326
  2,511
  2,703
  2,903
Earnings before tax, $m
  -141
  -1
  -6
  -14
  -23
  -36
  -53
  -73
  -98
  -127
  -162
  -197
  -243
  -294
  -351
  -413
  -480
  -553
  -631
  -714
  -802
  -895
  -992
  -1,095
  -1,201
  -1,313
  -1,429
  -1,550
  -1,676
  -1,807
  -1,943
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -141
  -1
  -6
  -14
  -23
  -36
  -53
  -73
  -98
  -127
  -162
  -197
  -243
  -294
  -351
  -413
  -480
  -553
  -631
  -714
  -802
  -895
  -992
  -1,095
  -1,201
  -1,313
  -1,429
  -1,550
  -1,676
  -1,807
  -1,943

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  347
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  476
  517
  752
  1,063
  1,465
  1,971
  2,593
  3,343
  4,230
  5,261
  6,441
  7,773
  9,260
  10,900
  12,692
  14,633
  16,720
  18,950
  21,320
  23,826
  26,465
  29,237
  32,138
  35,169
  38,330
  41,623
  45,048
  48,611
  52,313
  56,161
  60,159
Adjusted assets (=assets-cash), $m
  129
  517
  752
  1,063
  1,465
  1,971
  2,593
  3,343
  4,230
  5,261
  6,441
  7,773
  9,260
  10,900
  12,692
  14,633
  16,720
  18,950
  21,320
  23,826
  26,465
  29,237
  32,138
  35,169
  38,330
  41,623
  45,048
  48,611
  52,313
  56,161
  60,159
Revenue / Adjusted assets
  0.643
  0.242
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
  0.241
Average production assets, $m
  74
  110
  160
  227
  313
  421
  554
  714
  903
  1,123
  1,375
  1,660
  1,977
  2,327
  2,710
  3,124
  3,570
  4,046
  4,552
  5,087
  5,651
  6,243
  6,862
  7,510
  8,185
  8,888
  9,619
  10,380
  11,170
  11,992
  12,846
Working capital, $m
  193
  -12
  -18
  -26
  -35
  -48
  -62
  -81
  -102
  -127
  -155
  -187
  -223
  -263
  -306
  -353
  -403
  -457
  -514
  -574
  -638
  -705
  -775
  -848
  -924
  -1,003
  -1,086
  -1,172
  -1,261
  -1,353
  -1,450
Total debt, $m
  101
  237
  443
  718
  1,071
  1,516
  2,064
  2,724
  3,504
  4,411
  5,450
  6,623
  7,931
  9,374
  10,951
  12,659
  14,496
  16,458
  18,543
  20,749
  23,072
  25,510
  28,063
  30,731
  33,513
  36,410
  39,425
  42,559
  45,818
  49,204
  52,722
Total liabilities, $m
  318
  455
  661
  936
  1,289
  1,734
  2,282
  2,942
  3,722
  4,629
  5,668
  6,841
  8,149
  9,592
  11,169
  12,877
  14,714
  16,676
  18,761
  20,967
  23,290
  25,728
  28,281
  30,949
  33,731
  36,628
  39,643
  42,777
  46,036
  49,422
  52,940
Total equity, $m
  157
  62
  90
  128
  176
  237
  311
  401
  508
  631
  773
  933
  1,111
  1,308
  1,523
  1,756
  2,006
  2,274
  2,558
  2,859
  3,176
  3,508
  3,857
  4,220
  4,600
  4,995
  5,406
  5,833
  6,278
  6,739
  7,219
Total liabilities and equity, $m
  475
  517
  751
  1,064
  1,465
  1,971
  2,593
  3,343
  4,230
  5,260
  6,441
  7,774
  9,260
  10,900
  12,692
  14,633
  16,720
  18,950
  21,319
  23,826
  26,466
  29,236
  32,138
  35,169
  38,331
  41,623
  45,049
  48,610
  52,314
  56,161
  60,159
Debt-to-equity ratio
  0.643
  3.820
  4.920
  5.620
  6.090
  6.410
  6.630
  6.790
  6.900
  6.990
  7.050
  7.100
  7.140
  7.170
  7.190
  7.210
  7.220
  7.240
  7.250
  7.260
  7.260
  7.270
  7.280
  7.280
  7.290
  7.290
  7.290
  7.300
  7.300
  7.300
  7.300
Adjusted equity ratio
  -1.473
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -141
  -1
  -6
  -14
  -23
  -36
  -53
  -73
  -98
  -127
  -162
  -197
  -243
  -294
  -351
  -413
  -480
  -553
  -631
  -714
  -802
  -895
  -992
  -1,095
  -1,201
  -1,313
  -1,429
  -1,550
  -1,676
  -1,807
  -1,943
Depreciation, amort., depletion, $m
  2
  8
  10
  12
  15
  19
  23
  28
  35
  42
  50
  55
  66
  78
  90
  104
  119
  135
  152
  170
  188
  208
  229
  250
  273
  296
  321
  346
  372
  400
  428
Funds from operations, $m
  -220
  7
  3
  -2
  -9
  -18
  -30
  -45
  -63
  -85
  -112
  -142
  -177
  -216
  -260
  -308
  -361
  -418
  -479
  -544
  -613
  -687
  -763
  -844
  -929
  -1,017
  -1,109
  -1,204
  -1,304
  -1,407
  -1,515
Change in working capital, $m
  -44
  -4
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -25
  -28
  -32
  -36
  -40
  -43
  -47
  -50
  -54
  -57
  -60
  -64
  -67
  -70
  -73
  -76
  -79
  -83
  -86
  -89
  -93
  -96
Cash from operations, $m
  -176
  11
  9
  6
  1
  -6
  -15
  -27
  -42
  -61
  -83
  -110
  -141
  -177
  -217
  -262
  -311
  -364
  -422
  -484
  -550
  -620
  -694
  -771
  -852
  -937
  -1,026
  -1,118
  -1,215
  -1,315
  -1,418
Maintenance CAPEX, $m
  0
  -2
  -4
  -5
  -8
  -10
  -14
  -18
  -24
  -30
  -37
  -46
  -55
  -66
  -78
  -90
  -104
  -119
  -135
  -152
  -170
  -188
  -208
  -229
  -250
  -273
  -296
  -321
  -346
  -372
  -400
New CAPEX, $m
  0
  -37
  -50
  -67
  -86
  -108
  -133
  -160
  -189
  -220
  -252
  -285
  -317
  -350
  -383
  -414
  -446
  -476
  -506
  -535
  -564
  -592
  -620
  -647
  -675
  -703
  -731
  -761
  -791
  -822
  -854
Cash from investing activities, $m
  18
  -39
  -54
  -72
  -94
  -118
  -147
  -178
  -213
  -250
  -289
  -331
  -372
  -416
  -461
  -504
  -550
  -595
  -641
  -687
  -734
  -780
  -828
  -876
  -925
  -976
  -1,027
  -1,082
  -1,137
  -1,194
  -1,254
Free cash flow, $m
  -158
  -28
  -45
  -66
  -92
  -124
  -162
  -205
  -255
  -311
  -373
  -440
  -514
  -593
  -677
  -766
  -861
  -959
  -1,063
  -1,171
  -1,283
  -1,400
  -1,521
  -1,647
  -1,778
  -1,913
  -2,054
  -2,200
  -2,351
  -2,508
  -2,672
Issuance/(repayment) of debt, $m
  -2
  152
  207
  274
  354
  445
  548
  660
  780
  907
  1,039
  1,173
  1,308
  1,443
  1,577
  1,708
  1,837
  1,963
  2,085
  2,205
  2,323
  2,439
  2,553
  2,667
  2,782
  2,897
  3,015
  3,135
  3,258
  3,386
  3,519
Issuance/(repurchase) of shares, $m
  3
  22
  35
  51
  72
  97
  127
  163
  204
  251
  304
  357
  421
  491
  566
  646
  731
  820
  915
  1,015
  1,119
  1,227
  1,340
  1,458
  1,581
  1,708
  1,840
  1,978
  2,120
  2,269
  2,423
Cash from financing (excl. dividends), $m  
  1
  174
  242
  325
  426
  542
  675
  823
  984
  1,158
  1,343
  1,530
  1,729
  1,934
  2,143
  2,354
  2,568
  2,783
  3,000
  3,220
  3,442
  3,666
  3,893
  4,125
  4,363
  4,605
  4,855
  5,113
  5,378
  5,655
  5,942
Total cash flow (excl. dividends), $m
  -156
  145
  197
  259
  333
  418
  513
  618
  730
  847
  970
  1,090
  1,215
  1,341
  1,465
  1,587
  1,707
  1,824
  1,938
  2,049
  2,158
  2,266
  2,372
  2,478
  2,585
  2,692
  2,801
  2,913
  3,028
  3,146
  3,269
Retained Cash Flow (-), $m
  129
  -22
  -35
  -51
  -72
  -97
  -127
  -163
  -204
  -251
  -304
  -357
  -421
  -491
  -566
  -646
  -731
  -820
  -915
  -1,015
  -1,119
  -1,227
  -1,340
  -1,458
  -1,581
  -1,708
  -1,840
  -1,978
  -2,120
  -2,269
  -2,423
Prev. year cash balance distribution, $m
 
  116
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  239
  162
  208
  261
  321
  386
  455
  525
  596
  666
  732
  794
  850
  900
  942
  976
  1,003
  1,022
  1,035
  1,040
  1,039
  1,032
  1,020
  1,004
  984
  961
  935
  907
  877
  847
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  229
  148
  181
  215
  249
  280
  307
  328
  343
  349
  348
  339
  323
  302
  276
  248
  218
  188
  159
  132
  107
  86
  67
  51
  38
  28
  20
  14
  10
  6
Current shareholders' claim on cash, %
  100
  94.9
  89.9
  85.1
  80.6
  76.3
  72.5
  68.8
  65.5
  62.4
  59.6
  56.9
  54.5
  52.2
  50.0
  48.0
  46.1
  44.2
  42.5
  40.9
  39.4
  37.9
  36.5
  35.2
  33.9
  32.7
  31.5
  30.4
  29.4
  28.3
  27.3

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that is in Phase III clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound for the treatment of glaucoma. Further, the company’s development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

FINANCIAL RATIOS  of  Lexicon Pharmaceuticals (LXRX)

Valuation Ratios
P/E Ratio -12.4
Price to Sales 21
Price to Book 11.1
Price to Tangible Book
Price to Cash Flow -9.9
Price to Free Cash Flow -9.9
Growth Rates
Sales Growth Rate -36.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -100%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 22
Current Ratio 0
LT Debt to Equity 54.1%
Total Debt to Equity 64.3%
Interest Coverage -23
Management Effectiveness
Return On Assets -23.9%
Ret/ On Assets - 3 Yr. Avg. -16.7%
Return On Total Capital -43.6%
Ret/ On T. Cap. - 3 Yr. Avg. -26.4%
Return On Equity -63.7%
Return On Equity - 3 Yr. Avg. -36.5%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -160.2%
EBITDA Margin - 3 Yr. Avg. -192%
Operating Margin -165.1%
Oper. Margin - 3 Yr. Avg. -199.7%
Pre-Tax Margin -169.9%
Pre-Tax Margin - 3 Yr. Avg. -202.8%
Net Profit Margin -169.9%
Net Profit Margin - 3 Yr. Avg. -202.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

LXRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the LXRX stock intrinsic value calculation we used $83 million for the last fiscal year's total revenue generated by Lexicon Pharmaceuticals. The default revenue input number comes from 2016 income statement of Lexicon Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our LXRX stock valuation model: a) initial revenue growth rate of 50% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for LXRX is calculated based on our internal credit rating of Lexicon Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Lexicon Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of LXRX stock the variable cost ratio is equal to 98.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for LXRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.9% for Lexicon Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Lexicon Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the LXRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for LXRX are equal to 88.6%.

Life of production assets of 59.3 years is the average useful life of capital assets used in Lexicon Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for LXRX is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $157 million for Lexicon Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 101.403 million for Lexicon Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Lexicon Pharmaceuticals at the current share price and the inputted number of shares is $1.7 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 55.65 26.07  str.sell
SNY Sanofi ADR 47.71 50.76  hold
ILMN Illumina 172.75 71.07  str.sell
NUS Nu Skin Enterp 64.10 85.70  buy

COMPANY NEWS

▶ 3 Top Healthcare Stocks You Haven't Thought Of   [Jun-18-17 09:07AM  Motley Fool]
▶ 3 Top-Performing Biotech Stocks This Week   [Jun-16-17 07:41AM  Motley Fool]
▶ Company News for June 12, 2017   [Jun-12-17 10:15AM  Zacks]
▶ Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial   [Jun-09-17 08:45AM  24/7 Wall St.]
▶ Lexicon reports 1Q loss   [May-03-17 05:02AM  Associated Press]
▶ 3 Top Biotech Stocks to Buy in April   [Apr-03-17 04:23PM  Motley Fool]
▶ 3 Top Biotech Stocks to Buy in April   [04:23PM  at Motley Fool]
▶ What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track   [Mar-31-17 04:10PM  Investor's Business Daily]
▶ 3 Stocks We're Watching in the First Quarter   [Feb-15-17 07:34PM  at Motley Fool]
▶ 5 Small-Cap Biotech Stocks to Buy in February   [Jan-26-17 04:28PM  at Motley Fool]
▶ 5 Biotech Stocks You'll Want to Watch in the 1st Quarter   [Jan-18-17 09:26AM  at Motley Fool]
▶ Lexicon Diabetes Drug Shows Phase 2 Promise (LXRX)   [Oct-25-16 02:24PM  at Investopedia]
▶ 3 Biotechs With Potential Big-Time Upside   [Sep-26-16 04:28PM  at Motley Fool]
Stock chart of LXRX Financial statements of LXRX Annual reports of LXRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.